PanBlok™
PanBlok™ is Protein Sciences' pandemic influenza vaccine candidate. The current vaccine is comprised of purified recombinant hemagglutinin antigen (active ingredient) from the H5N1 avian influenza. This product has attained Phase II clinical development through a partnership with UMN Pharma in Japan.
Human subjects "primed" with PanBlok-H5 had enhanced immune response to subsequent vaccination compared to naïve subjects.1
PanBlok-H5 Advantages:
- Underlying manufacturing technology provides ability for rapid response to a pandemic strain emergence
- No live influenza viruses used in production -no risk releasing pandemic live virus in the environment
- Authentic strain match
- Priming response demonstrated
- No preservatives (i.e. no thimerisol)
- No egg proteins present
References:
1. Goji NA, Nolan C, Hill H, Wolff M, Noah DL, Williams TB, Rowe T, Treanor JJ. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008 Sep 1; 198(5):635-41.
